Wedbush Reaffirms Outperform Rating for Perspective Therapeutics (NYSE:CATX)

Wedbush reiterated their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a research report released on Thursday morning,RTT News reports. The firm currently has a $11.00 price objective on the stock, down from their previous price objective of $20.00.

Several other equities research analysts also recently commented on CATX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Truist Financial initiated coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They set a “buy” rating and a $21.00 price target on the stock. Bank of America initiated coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They set a “buy” rating and a $24.00 price target on the stock. Royal Bank of Canada dropped their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research report on Friday, August 16th. Finally, UBS Group initiated coverage on Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target on the stock. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $20.29.

Perspective Therapeutics Stock Down 51.2 %

Shares of Perspective Therapeutics stock opened at $3.01 on Thursday. The company has a fifty day moving average price of $11.75. Perspective Therapeutics has a fifty-two week low of $2.28 and a fifty-two week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The business had revenue of $0.37 million during the quarter. Equities analysts anticipate that Perspective Therapeutics will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company raised its stake in shares of Perspective Therapeutics by 8.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after acquiring an additional 1,672 shares in the last quarter. Sykon Capital LLC raised its stake in shares of Perspective Therapeutics by 4.7% in the 2nd quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after acquiring an additional 1,717 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Perspective Therapeutics by 5.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock valued at $783,000 after acquiring an additional 3,211 shares in the last quarter. US Bancorp DE raised its stake in shares of Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after acquiring an additional 3,866 shares in the last quarter. Finally, nVerses Capital LLC bought a new position in shares of Perspective Therapeutics in the 3rd quarter valued at approximately $57,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.